Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4410-4419

  Kyaw, Tin ^a,b   Tay, Christopher ^a,b   Khan, Abdul ^a,b   Dumouchel, Vanessa ^a,b   Cao, Anh ^b   To, Kelly ^a   Kehry, Merilyn ^c   Dunn, Robert ^c   Agrotis, Alex ^a   Tipping, Peter ^b   Bobik, Alex ^a   Toh, Ban Hock ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN G2A ANTIBODY; RAG2 PROTEIN; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; CONTROLLED STUDY; HYPERLIPIDEMIA; LIPID DIET; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; B-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77958125881     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000033     Document Type: Article

References (33)

1. Houtkamp, M. A., O. J. de Boer, C. M. van der Loos, A. C. van der Wal, and A. E. Becker. 2001. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J. Pathol. 193:263-269.
2. Ylä-Herttuala, S., W. Palinski, S. W. Butler, S. Picard, D. Steinberg, and J. L. Witztum. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14:32-40.
3. Zhou, X., and G. K. Hansson. 1999. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of apolipoprotein E knockout mice. Scand. J. Immunol. 50:25-30.
4. Weber, C., A. Zernecke, and P. Libby. 2008. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 8:802-815.
5. Galkina, E., and K. Ley. 2009. Immune and inflammatory mechanisms of atherosclerosis (p). Annu. Rev. Immunol. 27:165-197.
6. Major, A. S., S. Fazio, and M. F. Linton. 2002. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 22:1892-1898.
7. Lewis, M. J., T. H. Malik, M. R. Ehrenstein, J. J. Boyle, M. Botto, and D. O. Haskard. 2009. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120:417-426.
8. Hansson, G. K., and J. Nilsson. 2009. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin. Immunopathol. 31:95-101.
9. Dörner, T., A. Radbruch, and G. R. Burmester. 2009. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol. 5:433-441.
10. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50:2580-2589.
11. Ramos-Casals, M., C. Díaz-Lagares, and M. A. Khamashta. 2009. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum. 61:1281-1282.
12. Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al; HERMES Trial Group. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358:676-688.
13. Yu, S., R. Dunn, M. R. Kehry, and H. Braley-Mullen. 2008. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD. H-2h4 mice. J. Immunol. 180:7706-7713.
14. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179:3351-3361.
15. Hamel, K., P. Doodes, Y. Cao, Y. Wang, J. Martinson, R. Dunn, M. R. Kehry, B. Farkas, and A. Finnegan. 2008. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 180:4994-5003.
16. Hu, C. Y., D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, F. S. Wong, M. J. Shlomchik, and L. Wen. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117:3857-3867.
17. Paigen, B., A. Morrow, P. A. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231-240.
18. Bas, A., G. Forsberg, S. Hammarström, and M. L. Hammarström. 2004. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand. J. Immunol. 59:566-573.
19. (T)) Method. Methods 25:402-408.
20. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174:4389-4399.
21. Wells, S. M., A. B. Kantor, and A. M. Stall. 1994. CD43 (S7) expression identifies peripheral B cell subsets. J. Immunol. 153:5503-5515.
22. Freigang, S., S. Hörkkö, E. Miller, J. L. Witztum, and W. Palinski. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehydemodified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1972-1982.
23. Edwards, J. C., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6:394-403.
24. Hoyer, B. F., R. A. Manz, A. Radbruch, and F. Hiepe. 2005. Long-lived plasma cells and their contribution to autoimmunity. Ann. N. Y. Acad. Sci. 1050:124-133.
25. Wen, L., S. J. Roberts, J. L. Viney, F. S. Wong, C. Mallick, R. C. Findly, Q. Peng, J. E. Craft, M. J. Owen, and A. C. Hayday. 1994. Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta (+) T cells. Nature 369:654-658.
26. Reininger, L., T. Radaszkiewicz, M. Kosco, F. Melchers, and A. G. Rolink. 1992. Development of autoimmune disease in SCID mice populated with long-term "in vitro" proliferating (NZB x NZW) F1 pre-B cells. J. Exp. Med. 176:1343-1353.
27. Lund, F. E. 2008. Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 20:332-338.
28. Harris, D. P., L. Haynes, P. C. Sayles, D. K. Duso, S. M. Eaton, N. M. Lepak, L. L. Johnson, S. L. Swain, and F. E. Lund. 2000. Reciprocal regulationof polarized cytokine production by effector B and T cells. Nat. Immunol. 1:475-482.
29. Chan, O. T., M. P. Madaio, and M. J. Shlomchik. 1999. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J. Immunol. 163:3592-3596.
30. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639-1648.
31. Sung, S. S., L. K. Jung, J. A. Walters, W. Chen, C. Y. Wang, and S. M. Fu. 1988. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J. Exp. Med. 168:1539-1551.
32. Corcione, A., L. Ottonello, G. Tortolina, P. Tasso, F. Ghiotto, I. Airoldi, G. Taborelli, F. Malavasi, F. Dallegri, and V. Pistoia. 1997. Recombinant tumor necrosis factor enhances the locomotion of memory and naive B lymphocytes from human tonsils through the selective engagement of the type II receptor. Blood 90:4493-4501.
33. Shlomchik, M. J. 2008. Sites and stages of autoreactive B cell activation and regulation. Immunity 28:18-28.